Is LLY Stock Setup For A Rerating?
Eli Lilly (LLY) stock trades at $963.33 per share, a market cap of $861.7B, and 34.1 times trailing earnings. Is that a fair price, or is there more going on here?
Where LLY Sits Today
- Valuation: P/E of 34.1 versus a 3-year average of 67.0 and a 3-year high of 114.2.
- Revenue: Revenue grew 47.4% over the last 12 months, with a 3-year CAGR of 37.9%.
- Net Margin: Running at 35.0% LTM, against a 3-year average of 22.8% and a 3-year peak of 35.0%.
While the table below shows the same picture in one place, you can internalize LLY’s current state better with a more detailed financial picture.
| LLY | |
|---|---|
| Sector | Health Care |
| Industry | Pharmaceuticals |
| P/E Ratio | 34.1 |
| P/E Ratio 3Y Avg | 67.0 |
| LTM* Revenue Growth | 47.4% |
| 3Y Avg Revenue Growth | 37.9% |
| LTM* Net Margin | 35.0% |
| 3Y Peak Net Margin | 35.0% |
| 3Y Avg Net Margin | 22.8% |
*LTM: Last Twelve Months
- Freeport-McMoRan Earnings: The Good, the Bad, and the Grasberg
- Can Newmont Keep Riding The Gold Rally Into 2027?
- Intel, Lam, KLA: Will Musk’s $120B Terafab Boost These Stocks?
- Get Paid 10% To Buy NVDA At A 30% Discount, Here’s How
- How CVS Health’s Transformation Is Facing A Hard Valuation Floor
- Is UBER Stock Undervalued At $80?
Revenue Compounding Does The Work
LLY has accelerated recently, but at these levels, gravity eventually takes over. We will not extrapolate peak performance, and instead, apply a structural fade to project 30.0% annually.
Even with these conservative guardrails, compounding moves the earnings base enough to deliver the upside here. Margins and multiples are not asked to stretch.
The 3-Year Math
A straightforward scenario, not a forecast. Here is what the numbers look like.
- Revenue grows at 30.0% annually (applying a structural fade to recent peak acceleration), and reaches $158.7B from $72.2B today.
- Net Margin eases from 35.0% to 31.3% as peak-level margins pull back toward the 3-year average of 22.8%.
- Earnings combine the two. The base moves to roughly $49.7B from $25.3B today, about a 97% jump.
- P/E compresses from 34.1 to 30.3. A lower growth regime earns a lower multiple. We actively penalize the valuation rather than pretending today’s PE persists through a slowdown.
Apply the projected multiple to the projected earnings base: stock price lands near $1687.29, a market cap of $1.5T against $861.7B today. That is roughly 75% above where the stock trades now.
Revenue compounding might be the key to LLY’s upside going forward. But did the same lever drive its recent move or was it something different?
What Has To Be True
The scenario assumes growth of 30.0% annually, intentionally faded below the LTM 47.4% pace. What has to be true is that growth settles at or above this modest rate. If it collapses entirely, the multiple in our scenario becomes hard to defend.
The 3-year horizon is a convenience. Whether this plays out over 3 years or 5, the stock price is likely to respond in a similar direction, as long as the trajectory holds.
When One Stock Isn’t The Whole Answer
A careful 3-year case on a single name is still a concentrated bet, as analysis of its volatility during past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book – partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.
The Trefis High Quality (HQ) Portfolio combines the analytical rigor with forward looking view across 30 stocks, with a consistent selection framework and a sizing and rebalancing discipline designed to deliver upside without the single-name risk you just read through here.
By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000.